Myriad Genetics, Inc.

NASDAQ:MYGN   3:59:53 PM EDT
32.57
-0.74 (-2.22%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)2.54B
Current PEN/A
Forward PE N/A
2yr Forward PE 1085.67
See more stats
Estimates Current Quarter
Revenue$165.68 Million
Adjusted EPS-$0.04
See more estimates
10-Day MA$33.59
50-Day MA$33.54
200-Day MA$29.30
See more pivots

Myriad Genetics, Inc. Stock, NASDAQ:MYGN

320 Wakara Way, Salt Lake City, Utah 84108
United States of America
Phone: +1.801.584.3600
Number of Employees: 2700

Description

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.